-
Something wrong with this record ?
Antileukotrienic phenethylamido derivatives of arylalkanoic acids in the treatment of ulcerative colitis
R. Junek, M. Kverka, A. Jandera, V. Panajotová, D. Šatínský, M. Macháček, M. Kuchař
Language English Country France
- MeSH
- Anti-Inflammatory Agents pharmacology chemical synthesis MeSH
- Hydrocarbons, Aromatic pharmacology chemical synthesis MeSH
- Financing, Organized MeSH
- Gastrointestinal Agents pharmacology chemical synthesis MeSH
- Rats MeSH
- Cells, Cultured MeSH
- Quantitative Structure-Activity Relationship MeSH
- Carboxylic Acids MeSH
- Leukocytes MeSH
- Receptors, Leukotriene B4 antagonists & inhibitors MeSH
- Colitis, Ulcerative drug therapy MeSH
- Structure-Activity Relationship MeSH
- Inflammation drug therapy MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
A series of arylalkanoic acid derivatives bearing methyl(phenethyl)amino groups were prepared and their inhibition of LTB(4) biosynthesis was evaluated. Regression analysis showed the slightly different parabolic dependences of this activity on lipophilicity of alpha-methyl and alpha-unsubstituted alkanoic acid derivatives. The relationship derived for alpha-unsubstituted alkanoic acids was extended by previously prepared group of similar derivatives of arylacetic acids without any change of regression coefficients and statistical criteria. It was concluded that the most active compounds belong to 2-arylpropanoic acid derivatives with lipophilicity close to logP(opt) (=6.97). But generally, the structural changes in the acidic part of compounds under study did not yield the substantial improvement of LTB(4) biosynthesis inhibition in comparison with the previously prepared series of derivatives IV. The anti-inflammatory effect of the compounds under study was evaluated in three animal models of inflammation and their possible utilization in the treatment of ulcerative colitis (UC) was followed. From 12 evaluated compounds, 4 compounds are more active in UC inhibition than the standard sulfasalazine but it can be stated that the change of connecting chain between aromatic ring and carboxyl did not bring about the important improvement of this activity in comparison with previous derivatives of arylacetic acids. Possible relation between LTB(4) biosynthesis inhibition and ulcerative colitis is seriously broken by the compound 8a with carbonyl as the additional functional group on the connecting chain between carboxyl and aromatic ring.
References provided by Crossref.org
- 000
- 03510naa 2200469 a 4500
- 001
- bmc11009899
- 003
- CZ-PrNML
- 005
- 20221005131017.0
- 008
- 110511s2009 fr e eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2008.02.030 $2 doi
- 035 __
- $a (PubMed)18406012
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Junek, Richard $7 xx0103668
- 245 10
- $a Antileukotrienic phenethylamido derivatives of arylalkanoic acids in the treatment of ulcerative colitis / $c R. Junek, M. Kverka, A. Jandera, V. Panajotová, D. Šatínský, M. Macháček, M. Kuchař
- 314 __
- $a Zentiva VUFB, a.s., 102 01 Prague 10, Czech Republic.
- 520 9_
- $a A series of arylalkanoic acid derivatives bearing methyl(phenethyl)amino groups were prepared and their inhibition of LTB(4) biosynthesis was evaluated. Regression analysis showed the slightly different parabolic dependences of this activity on lipophilicity of alpha-methyl and alpha-unsubstituted alkanoic acid derivatives. The relationship derived for alpha-unsubstituted alkanoic acids was extended by previously prepared group of similar derivatives of arylacetic acids without any change of regression coefficients and statistical criteria. It was concluded that the most active compounds belong to 2-arylpropanoic acid derivatives with lipophilicity close to logP(opt) (=6.97). But generally, the structural changes in the acidic part of compounds under study did not yield the substantial improvement of LTB(4) biosynthesis inhibition in comparison with the previously prepared series of derivatives IV. The anti-inflammatory effect of the compounds under study was evaluated in three animal models of inflammation and their possible utilization in the treatment of ulcerative colitis (UC) was followed. From 12 evaluated compounds, 4 compounds are more active in UC inhibition than the standard sulfasalazine but it can be stated that the change of connecting chain between aromatic ring and carboxyl did not bring about the important improvement of this activity in comparison with previous derivatives of arylacetic acids. Possible relation between LTB(4) biosynthesis inhibition and ulcerative colitis is seriously broken by the compound 8a with carbonyl as the additional functional group on the connecting chain between carboxyl and aromatic ring.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antiflogistika $x farmakologie $x chemická syntéza $7 D000893
- 650 _2
- $a kyseliny karboxylové $7 D002264
- 650 _2
- $a kultivované buňky $7 D002478
- 650 _2
- $a ulcerózní kolitida $x farmakoterapie $7 D003093
- 650 _2
- $a gastrointestinální látky $x farmakologie $x chemická syntéza $7 D005765
- 650 _2
- $a aromatické uhlovodíky $x farmakologie $x chemická syntéza $7 D006841
- 650 _2
- $a zánět $x farmakoterapie $7 D007249
- 650 _2
- $a leukocyty $7 D007962
- 650 _2
- $a kvantitativní vztahy mezi strukturou a aktivitou $7 D021281
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a receptory leukotrienu B4 $x antagonisté a inhibitory $7 D018102
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Kverka, Miloslav. $7 xx0208988
- 700 1_
- $a Jandera, Antonín. $7 _AN051979
- 700 1_
- $a Panajotová, Vladimíra $7 xx0089991
- 700 1_
- $a Šatínský, Dalibor $7 xx0019028
- 700 1_
- $a Macháček, Miloš, $d 1954-2016 $7 xx0014613
- 700 1_
- $a Kuchař, Miroslav, $d 1935- $7 jk01070734
- 773 0_
- $t European Journal of Medicinal Chemistry $w MED00001628 $g Roč. 44, č. 1 (2009), s. 332-344
- 910 __
- $a ABA008 $b x $y 2 $z 0
- 990 __
- $a 20110513111430 $b ABA008
- 991 __
- $a 20221005131013 $b ABA008
- 999 __
- $a ok $b bmc $g 839190 $s 703304
- BAS __
- $a 3
- BMC __
- $a 2009 $b 44 $c 1 $d 332-344 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a 2011-2B09/jvme